Telix Pharmaceuticals, an Australian pharmaceutical company, entered into an agreement to acquire ITM Isotope Technologies Munich for total consideration reaching up to $2.35bn. The transaction combines Telix’s existing pharmaceutical operations with ITM’s radioisotope manufacturing business and late-stage drug candidate ITM-11.
The deal structure involved an upfront payment of $1.65bn on a cash-free, debt-free basis, with additional contingent payments of up to $700m tied to regulatory and commercial milestones for ITM-11. The upfront consideration consisted of $1.25bn payable through the issuance of 105.8m Telix shares priced at $11.841 each, calculated using the company’s 30-day trailing volume-weighted average price at signing. These shares would be released as Nasdaq-listed American depositary receipts following applicable escrow periods. Telix would also assume $302m in ITM net debt at closing, with an additional $96m in management equity rollover and transaction costs borne by sellers.
Following completion, ITM shareholders were projected to hold 23.7% of Telix shares, while existing Telix shareholders would own 76.3%. ITM generated $273m in revenue in 2025 and demonstrated a compound annual growth rate of 40% spanning 2021 through 2025. The privately held company, established in 2004, manufactures radioisotopes including actinium-225, lutetium-177, and terbium-161, with distribution networks across more than 65 countries. Its primary pipeline asset, ITM-11 (lutetium-177 edotreotide), targets gastro-enteropancreatic neuroendocrine tumours and completed its primary Phase III clinical development program.
Contingent payments included up to $250m for FDA approvals across three indications and up to $450m based on ITM-11 global net sales exceeding $150m in the 2030 financial year, with milestone payments potentially made in cash or shares. The transaction was expected to close by the end of the 2026 financial year, pending Telix shareholder and regulatory approvals, with an extraordinary general meeting scheduled for November 2026.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI